TAMPA, Fla. — In this Healio Video Perspective from Telling It Like It Is, Steven M. Silverstein, MD, FACS, discusses safety data for Dextenza for the treatment of perioperative ocular pain and inflammation and allergic conjunctivitis.
Data collected from the IRIS Registry showed low adverse rates in more than 50,000 patients implanted with Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) that were “nearly identical” compared with results in patients who received topical drop therapy.
“The use of a dexamethasone insert perioperatively or to use in